Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.

Proceedings of the National Academy of Sciences of the United States of America - 6 Sept 2016

Bauer Matthias R, Joerger Andreas C, Fersht Alan R

Abstract excerpt

The tumor suppressor p53 has the most frequently mutated gene in human cancers. Many of p53's oncogenic mutants are just destabilized and rapidly aggregate, and are targets for stabilization by drugs. We found certain 2-sulfonylpyrimidines, including one named PK11007, to be mild thiol alkylators with anticancer activity in several cell lines, especially those with mutationally compromised p53. PK11007 acted by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkylating Agents
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crystallography, X-Ray

Share to Gene Expression Regulation, Neoplastic

Share to Pyrimidines

Share to Reactive Oxygen Species

Share to Sulfones

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 27551077
DOI: 10.1073/pnas.1610421113
PMCID: PMC5018792

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.PMID 27551077Read ↗

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read ↗

Mutant p53 reactivation by small molecules makes its way to the clinic.Semantic proximity Read ↗

P53: an ubiquitous target of anticancer drugs.Semantic proximity Read ↗

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.Semantic proximity Read ↗

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?Semantic proximity Read ↗

Targeting p53 for Novel Anticancer TherapySemantic proximity Read ↗

Chemical Variations on the p53 Reactivation ThemeSemantic proximity Read ↗

A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability.Semantic proximity Read ↗

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.Semantic proximity Read ↗

Mutant p53 rescue and modulation of p53 redox state.Semantic proximity Read ↗

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.Semantic proximity Read ↗

Mutant p53 as a target for cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.